Newswire & Press Release / Exelixis and Ipsen Initiate Phase 3 Pivotal Trial of Cabozantinib in Combination with Atezolizumab Versus Sorafenib – Pharma/BioTech/Nutrition – IPSEN Group – Newswire Today

Spread the love

Newswire & Press Release / Exelixis and Ipsen Initiate Phase 3 Pivotal Trial of Cabozantinib in Combination with Atezolizumab Versus Sorafenib – Pharma/BioTech/Nutrition – IPSEN Group Newswire Today

NewswireToday – /newswire/ – Alameda, CA, United States, 2018/12/05 – Clinical trial will also explore single-agent activity of cabozantinib in the first-line setting …

…read more

Source:: Alameda, California News By Google News

Start a Conversation

[ghozylab-instagram feed=26796]